Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01212471 · ClinicalTrials.gov registry record · Phase 3
A Dose Ranging Study to Evaluate Safety and Efficacy of Bromfenac Ophthalmic Solution in Dry Eye Disease
A Phase 3 study, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- Phase 3
- Development phase
- 840
- Enrollment target
NCT01212471 is a Phase 3 study that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 840 participants.
The verdict
NCT01212471, a Phase 3 study, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 840 participants
- Enrollment target
Study Summary
A dose ranging study to evaluate safety and efficacy of bromfenac ophthalmic solution in dry eye disease.
Interventions
- DRUG Placebo Comparator
- DRUG Bromfenac Ophthalmic Solution A
- DRUG Bromfenac Ophthalmic Solution B
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 840 participants |
| Start Date | 2010-09 |
| Est. Completion | 2011-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01212471
The ClinicalTrials.gov registry entry for NCT01212471 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 840 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch & Lomb Incorporated, which has 174 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo Comparator is the first listed.
NCT01212471 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01212471 about?
NCT01212471 is a clinical study titled "A Dose Ranging Study to Evaluate Safety and Efficacy of Bromfenac Ophthalmic Solution in Dry Eye Disease". A dose ranging study to evaluate safety and efficacy of bromfenac ophthalmic solution in dry eye disease.
What is the current status of trial NCT01212471?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 840 participants. The study started on 2010-09. Estimated completion is 2011-12.
What interventions are being tested in trial NCT01212471?
The interventions under investigation include: Placebo Comparator (DRUG), Bromfenac Ophthalmic Solution A (DRUG), Bromfenac Ophthalmic Solution B (DRUG).
Who is sponsoring clinical trial NCT01212471?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.